Soliris (eculizumab), already approved in Japan for adults with generalized myasthenia gravis (gMG), has now become the first therapy to win approval in the Asian nation for treating children and adolescents with this type of the autoimmune condition. The expanded use was granted by the Japanese Ministry of…
More than half of myasthenia gravis (MG) patients take more than a year to be diagnosed from symptom onset and about two-thirds feel the diagnostic process was long and/or very complicated, according to an online survey in Poland. Also, while 7 out of 10 respondents said their current treatment…
Pregnant women with myasthenia gravis (MG) are particularly susceptible to severe disease-related complications, usually caused by generalized muscle weakness, which can put the mother and child at risk, according to a recent review study. Newborns should also be monitored for symptoms of transient neonatal MG, a form of…
A thymectomy, or surgical removal of the thymus gland, was effective for children and adolescents with myasthenia gravis (MG), as indicated by lower medication use and healthcare utilization after surgery, a study reports. Demographic characteristics like age, sex, ethnicity, insurance payer type, residential region, and the surgical approach…
Having a thymoma, or a tumor in the thymus gland, can make a severe complication of myasthenia gravis (MG) — known as a myasthenic crisis — more likely, a Turkish study suggests. “We found that thymoma increased the risk of developing a myasthenic crisis, and also increased the risk of…
People with myasthenia gravis (MG) experience a lower health-related quality-of-life impact, face a higher medical burden, and require more assistance from caregivers compared with the general population, according to data pulled from two international studies. MG patients also were more likely to take sick leave from work and to…
A new therapy that combines plasmapheresis, or plasma exchange, with the removal of certain immune cells from a person’s blood was seen to result in better outcomes among people with severe myasthenia gravis (MG) than were…
The home infusion company KabaFusion has announced that UCB has tapped it as a limited U.S. distribution partner for Rystiggo (rozanolixizumab-noli), the first therapy approved for adults with the two most common subtypes of generalized myasthenia gravis (gMG). Following its June approval by the U.S. Food…
The approval of Soliris (eculizumab) in the European Union now extends to children and adolescents, ages 6 to 17, with generalized myasthenia gravis (gMG). The European Commission decision covers Soliris’ use in children who have refractory disease, meaning they have failed to respond to standard treatments, and are…
Most people with childhood-onset myasthenia gravis (CMG) experience milder clinical symptoms and a better prognosis than those with adult forms of the disease, according to a recent study in China. For most CMG patients, their disease could be safely controlled with prednisone and other immunosuppressive agents. Researchers also found…
Get regular updates to your inbox.